Hormonal patterns, steroid receptors and morphological pictures of endometrium in hyperstimulated IVF cycles.
OBJECTIVE
The purpose of this contribution is to investigate the pathophysiology of the abnormal endometrial development in hyperstimulated IVF cycles.


METHODS
In 12 IVF-patients who did not have embryo transfer because of failure of oocyte fertilization, serum values of 17 beta-estradiol, progesterone, FSH, LH, total and free testosterone, and androstenedione were measured on the pick-up day and were evaluated with respect to the values normally expressed in the day of ovulation; in the endometrial specimens collected 2 days later, at the time of embryo replacement, estrogen and progesterone receptors were immunohistochemically determined and dating by the Noyes method was performed.


RESULTS
17 beta-Estradiol values are constantly higher, and progesterone levels are, only in four cases, higher than expected for the day of ovulation in a natural cycle. These hormonal patterns can only partially explain the pattern of steroid receptors: progesterone receptors are expressed sparsely both in glands and stroma, while estrogen receptors are abundant in the glands and absent in the stroma. In 11 of 12 patients an abnormal endometrial development with stromal advancement was observed: this morphological picture of the endometrium could partially be explained only in the four cases presenting high progesterone levels by serum values and endometrial receptor content of estrogen and progesterone.


CONCLUSIONS
The abnormal endometrial development in hyperstimulated IVF cycles could only in part be explained by estrogen and progesterone, and other factors have to be considered.
Noci
I
I
Department of Gynaecology and Obstetrics, University of Florence, Italy.
Borri
P
P
Coccia
M E
ME
Criscuoli
L
L
Scarselli
G
G
Messeri
G
G
Paglierani
M
M
Moncini
D
D
Taddei
G
G
D000735:Androstenedione / Q000097:blood; D001706:Biopsy; D004717:Endometrium / Q000473:pathology* / Q000503:physiopathology*; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000097:blood; D006728:Hormones / Q000097:blood*; D006801:Humans; D007248:Infertility, Male / Q000628:therapy; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010062:Ovulation Induction / Q000009:adverse effects; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D013739:Testosterone / Q000097:blood
D006728:Hormones; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013739:Testosterone; D000735:Androstenedione; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone